East China Medicine: Phase II clinical trial of highly selective JAK1 inhibitor VC005 tablets for vitiligo has completed enrollment.

Recently, the Phase II clinical study of the second-generation highly selective JAK1 inhibitor VC005 tablets for the oral treatment of non-segmental vitiligo, independently developed by the strategic partner of East China Pharmaceutical, Jiangsu Weiker Pharmaceutical Technology Co., Ltd., has successfully completed enrollment of all subjects.